08.11.2014 Views

Mental health policy and practice across Europe: an overview

Mental health policy and practice across Europe: an overview

Mental health policy and practice across Europe: an overview

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Psychopharmaceuticals in <strong>Europe</strong> 153<br />

The <strong>Europe</strong><strong>an</strong> Union<br />

If we examine the figures for the <strong>Europe</strong><strong>an</strong> Union (EU-15) in more detail over<br />

the decade of the 1990s (see Table 7.3), while the overall number of SUs prescribed<br />

rose by about 19 per cent, prescribing of tr<strong>an</strong>quillizers, sedatives <strong><strong>an</strong>d</strong><br />

hypnotics remained relatively stable, showing a slight growth over the period of<br />

around 5 per cent. Prescribing of <strong>an</strong>tipsychotics has risen by 17 per cent, mostly<br />

as a result of the growth in the market for the newer ‘atypicals’, <strong><strong>an</strong>d</strong> psychostimul<strong>an</strong>ts<br />

rose by almost 90 per cent from a low base. However, the major<br />

growth area was in <strong>an</strong>tidepress<strong>an</strong>t drugs: prescribing of <strong>an</strong>tidepress<strong>an</strong>ts rose by<br />

almost 50 per cent <strong>across</strong> this decade.<br />

The figures <strong><strong>an</strong>d</strong> trends are clearest if expressed as SUs per 1000 population (see<br />

Table 7.4). Once again, prescribing of tr<strong>an</strong>quillizers, sedatives, hypnotics <strong><strong>an</strong>d</strong><br />

<strong>an</strong>tipsychotics remained relatively stable over the decade. The most marked<br />

rises were shown in psychostimul<strong>an</strong>ts – where prescribing increased tenfold<br />

– <strong><strong>an</strong>d</strong> <strong>an</strong>tidepress<strong>an</strong>ts – where prescribing almost doubled over the period,<br />

<strong>an</strong> increase almost entirely due to the 14-fold increase in prescriptions for<br />

SSRI-type pharmaceuticals (see Table 7.5).<br />

Table 7.3 Psychiatric drug prescribing 1990–2000 in <strong>Europe</strong> (st<strong><strong>an</strong>d</strong>ard dosage units,<br />

thous<strong><strong>an</strong>d</strong>s)<br />

1990 1992 1994 1996 1998 2000<br />

Tr<strong>an</strong>quillizers 7,513,609 7,571,866 7,438,466 7,836,741 7,889,968 8,127,616<br />

Antidepress<strong>an</strong>ts 3,399,914 3,855,187 4,261,443 5,237,285 5,909,638 6,451,185<br />

Sedatives <strong><strong>an</strong>d</strong> 5,277,560 5,472,512 5,476,647 5,782,375 5,849,562 5,626,615<br />

hypnotics<br />

Antipsychotics – all 2,486,725 2,737,709 2,728,829 2,890,676 2,921,099 3,015,128<br />

Psychostimul<strong>an</strong>ts 12,069 14,785 18,412 36,656 62,605 113,005<br />

Total 18,689,877 19,652,059 19,923,797 21,783,733 22,632,872 23,333,549<br />

Source: IMS Health Second Study. See Note 1.<br />

Table 7.4 Psychiatric drug prescribing 1990–2000 in <strong>Europe</strong> (st<strong><strong>an</strong>d</strong>ard dosage units<br />

per 1000 population)<br />

1990 1992 1994 1996 1998 2000<br />

Tr<strong>an</strong>quillizers 20,599 20,758 20,393 21,484 21,630 22,282<br />

Antidepress<strong>an</strong>ts 9,321 10,569 11,683 14,358 16,201 17,686<br />

Sedatives <strong><strong>an</strong>d</strong> hypnotics 14,468 15,003 15,014 15,852 16,037 15,425<br />

Antipsychotics – all 6,817 7,505 7,481 7,925 8,008 8,266<br />

Psychostimul<strong>an</strong>ts 33 41 50 100 172 310<br />

Total 51,238 53,876 54,621 59,720 62,048 63,969<br />

Source: IMS Health Second Study. See Note 1.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!